Business
Annual Results for period ended 30 September 2025
Nuformix plc announced its annual results for the year ended 30 September 2025, reporting a net asset value of £754,934 and a loss for the year of £652,586, a significant improvement from the prior year's loss of £3,641,487. The company's lead program, NXP002, targeting Idiopathic Pulmonary Fibrosis (IPF), received Orphan Drug Designation (ODD) in Europe and has a pending application in the US, with preclinical data showing promising anti-fibrotic and anti-inflammatory effects. The company also advanced its NXP004 oncology program and NXP001 program, though NXP002 remains the priority. Fundraising efforts, including a £300,000 placing and subscription in November 2024, a £168,750 subscription in February 2025, a £210,000 placing in May 2025, and a £228,081 Open Offer in November 2025, have provided funds to advance partnering discussions for NXP002 and for general corporate purposes, though future fundraising will be required. The company's cash balance stood at £97,550 as of 30 September 2025. Disclaimer*
About this update from Nuformix Plc
[{"type":"text","content":"\n\n27 January 2026\n \nNuformix plc\n \n(\"Nuformix\" or the \"Company\")\n \nAnnual Results for the period ended 30 September 2025\n \nNuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its audited results for the year ended 30 September 2025.\n \nNon-Executive Directors' Statement\n \nThe key priority for the Directors is to focus on the Company's NXP002 lead programme and specifically to find a business development partner. The Group operates a lean structure with the limited Board and brings in specialist consultants, experts in their field, to support the business as required.\n \nPipeline\n \nNuformix has a small pipeline of preclinical assets in development to address the high unmet medical need in fibrosis and oncology. We target solutions using our expertise to develop and file patent applications on novel crystalline forms of existing, marketed drugs, that have improved physical properties, with the aim of developing novel products in new indications to create attractive commercial opportunities. Importantly, the commercial opportunity is optimised when the repurposed product is differentiated from the original marketed product by way of either dose, route of administration or presentation.\n \nDrug repurposing is a well-known and successful strategy for enhancing the therapeutic and commercial value of marketed drugs. Such development strategies typically offer a greater probability of success compared to developing newly discovered drugs. This is due to the existing data that has been generated on the marketed drug, which can serve as an evidence-base for safety and efficacy in envisaged novel products. This existence of data may also result in lower overall development costs, shorter development timelines and reduced risk in development.\n \nThe Group's business model is to take its assets through key value inflection points before partnering or licensing its IP. We conduct research and development (\"R&D\") activities through out-sourcing, to enable access to different types of expertise that are needed for effective R&D and to minimise our operational costs. The Group has a strong network of external contractors, with whom we have had relationships over many ye...